As a selective inhibitor of BRAF kinase, dabrafenib has shown potent anti‐tumour activities in patients with BRAFV600E mutant anaplastic thyroid cancer. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.